Immutep Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Immutep Limited (IMMP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Immutep Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 7M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+517.4% annualized vs trailing 12 months).
- Scale: Immutep Limited ranks #242 of 542 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Immutep Limited accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IMMP Sales vs. its Competitors, Q4 2025
Immutep Limited generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.1% year over year, combined, vs 31.8% for Immutep Limited. Immutep Limited's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Immutep Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Immutep Limited | - | Yes | Yes | No |
| High-Confidence Competitors (17) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IMMP Stock Performance relative to its Competitors
IMMP Stock Performance relative to High-Confidence Competitors
IMMP Stock Performance relative to Similar-Size Competitors
IMMP Stock Performance relative to Similar Growth & Profitability Competitors
Immutep Limited's Comment on Competition and Industry Peers
Immutep Limited's Competitors Named by the Company
Competitive relationships identified from Immutep Limited reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bicara Therapeutics Inc | Company report | 85% |
| Eisai Co Ltd. | Company report | 85% |
| ImmunityBio, Inc | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Hoffmann-La Roche Ltd. | Company report | 85% |
| AbbVie, Inc. | Company report | 85% |
| Gilead Sciences Inc. | Company report | 85% |
| Arcus Biosciences Inc. | Company report | 85% |
| Curevac NV | Company report | 85% |
| Idera Pharmaceuticals, Inc. | Company report | 85% |
| Merck & Co | Company report | 85% |
| Birdie Biotech, Inc. | Company report | 85% |
| GlaxoSmithKline plc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Regeneron Pharmaceuticals, Inc. | Company report | 85% |
| AstraZeneca PLC | Company report | 85% |
| Checkmate Pharmaceuticals, Inc. | Company report | 85% |
| Amgen Inc. | Company report | 85% |
| Innate Immunotherapeutics Ltd. | Company report | 85% |
| BioLineRx Ltd. | Company report | 85% |
| Immunomedics, Inc. | Company report | 85% |
| Oncosec Medical, Inc. | Company report | 85% |
| Aduro Biotech, Inc. | Company report | 85% |
Company report basis, confidence, active dates and source counts for Immutep Limited's named competitors require a Commercial License.
Methodology: relationships are extracted from Immutep Limited reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.